Recent Updates
Recently added Catalysts
INO Positive Sentiment

INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023

Key Takeaway: INOVIO Pharmaceuticals, Inc. has announced that it will release its first quarter 2023 financial results on May 10, 2023, after market close. The company will host a live conference call and webcast at 4:30 p.m. ET following the results announcement, which will include a general business update and a Q&A session with analysts. INOVIO continues its focus on developing DNA medicines to combat HPV-associated diseases and cancer.
Price reaction · baseline $9.3732 (2023-04-27 close) · hit after-hours · clean, no other INO news in the window
day 0 close
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • INOVIO is set to provide its first quarter 2023 financial results, indicating ongoing business operations.
  • The company is focused on developing important DNA medicines for HPV-associated diseases and cancers.
  • A live conference call will allow for direct communication with analysts, enhancing transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
VGX-410
Phase 2 · Hepatitis C Virus Infection

Full Press Release Details

PLYMOUTH MEETING, Pa., April 28, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2023 financial results will be released after the market close on May 10, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.

Frequently Asked Questions

When will INOVIO release its Q1 2023 financial results?

INOVIO will release its Q1 2023 financial results on May 10, 2023.

What time is the INOVIO conference call on financial results?

The conference call will be held at 4:30 p.m. ET on May 10, 2023.

How can I listen to INOVIO's presentation?

You can listen to the presentation live and archived at http://ir.inovio.com.

What does INOVIO specialize in?

INOVIO specializes in developing DNA medicines for HPV-related diseases and cancer.

What device does INOVIO use for DNA medicine delivery?

INOVIO uses its proprietary CELLECTRA® device for DNA medicine delivery.

Last updated: Apr 28, 2023